• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/34

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

34 Cards in this Set

  • Front
  • Back
HAV
Characteristics
Picornaviridae
naked
+ssRNA
2-3 incubation, short
low mortality
NO CARRIER OR CHRONIC DISEASE
Fecal-Oral mostly
vaccine
HAV
Lab Tests
Anti-HAV: Exposed, vaccinated
Anti-HAV IgM: Recently vaccinated (3 months)
HAV
People at risk
travelrs to endemic countries
homosexuals and bisexual men (ryan, you need the vaccine)
drug users, chronic liver disease
American Indians and Alaskian natives
HBV
Characteristics
Hepadnaviridae
enveloped; circular dsDNA
parenteral spread (blood and body fluid)
6 wk to 6 mo. incubation period (long)
HBV
Effects
Chronic hepatitis high for children under 5 y.o. (60%)
can lead to cancer
vaccine
HBV
Lab Tests
HBV surface antigen: present with active infection
HBV core antigen: no test
HBV e antigen: DNA Poly; active infection
HBV
Epi
75-90% incidence in Asia and Middle East
80% of infants born to infected mothers
HBV
Effects
heptatocellular necrosis
portal inflammation
lobular inflammation
ribrosis and cirrhosis
HBV
Positive Clinical Results
HBsAg
Infected, Carrier
HBV
Positive Clinical Results
Anti-HBs
Immunity, vaccinated, had disease
HBV
Positive Clinical Results
Anti-HBc
Infected
HBV
Positive Clinical Results
Anti-HBc IgM
Recently infected, 3-6 mo.
HBV
Positive Clinical Results
HBeAg
highly infectious
HBV
Positive Clinical Results
HBV viral DNA
Infected, Chronic Disease Activity
Window
Period at about 2 months of HBV infection
where no surface antigen present and no antibodies to antigen
test with anti-HBc and anti-HBc IgM
Test for chronic HBV
HBsAg
Total anti-HBc
HVB Vaccine
3 for kids
give to susceptible groups, healthcare workers, sexual contacts
HVB Therapy
Interferon alpha for 16 wk
Lamivudiine
Adefovir
In this order
HCV
Characteristics
Flaviviridae
Enveloped
+ssRNA
Incubation 2-26 weeks
HCV
Infection
Acute (mild)
cryoglobulinemia (antibodies that accumulate at cold temp)
aplasic anemia
80% infected are chronic carriers
cirrhosis in 20%
HCV
Lab Tests
anti-HCV EIA: Screen for infected, chronic case
anti-HCV RIBA: Confirmation for infected, chronic case
HCV RT-PCR: active infection
Do EIA first, if + then confirm with one of the others.
If PCR confirmaiton is negative do RIBA
HCV
Factors Promoting Progression
alcohol
over 40 yo
HIV
HBV
HCV
Perinatal Transmission
6% rate of transmission
17% in women with HIV
No association wiht breastfeeding or delivery methods
infants do well
HCV
Transmission
Sexual in ~20%, rare
Blood
HCV
Who should get tested?
(4)
injected drugs
intranasal cocaine
hemodialysis
liver disease
HCV
Treatment
30-40% respond to antivirals interferon and ribavirin
vaccinate v. HPV
No vaccination!
limit alcohol
1 genotype hardest to treat
24 wk and check progress, if make progress another 24 wks
pegylated interferon alpha: better but has many side effects
too much info on this card. FML
HDV
Characteristics
defective virus; required HBV for replication
circular ssRNA
HBV envelop
parenteral transmission
Incubation Period: 6 wk-6 mo.
HDV
Clinical
Lead to cirrhosis
HBV-HDV coinfection severe acute disease; low risk fro chronic
HBV-DVS super infection:
usually chronic; high risk for liver disease
HDV
Transmission
IV drugs
doing the nasty.
Ryan's Mom
Niiice. Sexy time. (Borat voice).
HEV - Like HAV
Characteristics
Enteric
fecal oral
developing countries
contaminated water
incubation: 2-8 weeks
HEV
Disease States
high mortality (20%) among pregnant women
no chronic case
no treatment
HEV
Prevention
Avoid contaminated water
uncooked shellfish
uncooke fruit/vegetables
HGV
Characteristics
flaviviridae
enveloped
+ssRNA
incubation 1-4 mo
prevalence: 3-10% or 25% in high risk groups.